Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
60 hedge funds and large institutions have $15.3M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 11 closing their positions.
319% more call options, than puts
Call options by funds: $381K | Put options by funds: $91K
2% less capital invested
Capital invested by funds: $15.6M → $15.3M (-$263K)
5% less funds holding
Funds holding: 63 → 60 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WE
Wealth Effects
Boston,
Massachusetts
|
+$729K |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$161K |
| 3 |
GJL
Gendell Jeffrey L
|
+$123K |
| 4 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$52.7K |
| 5 |
TCOT
Trust Company of Toledo
Holland,
Ohio
|
+$41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$735K |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$577K |
| 3 |
BlackRock
New York
|
-$93.7K |
| 4 |
Millennium Management
New York
|
-$93.7K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$71K |
SEEL Hedge Fund Activity: Q1 2023 in Review
60 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2023, worth a combined $15.3M — down 1.7% from $15.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SEEL and 8 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Wealth Effects, opening a new position worth an estimated $729K. The largest seller was Group One Trading, cutting an estimated $735K.
- 60 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2023, down from 63 in Q4 2022.
- Funds reported $15.3M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2023, down 1.7% quarter-over-quarter.
- 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2023 and 11 closed out, a net change of -3 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2023 was Wealth Effects, an estimated $729K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2023 was Group One Trading, an estimated $735K sold.
Based on aggregated 13F filings for Q1 2023.